GlassScriptPhysician profile
Margaux E Zanetti
NPI 1023683257
$2,729.79
in general payments reported to CMS, 2019-2025
24 companies · $1,344 in 2025
The $1,344 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $88.16 · 2022: $355 · 2023: $178 · 2024: $765 · 2025: $1,344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,286.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $448.47 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $444.49 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $318.34 | 2023-2025 | Mavyret |
| Lilly USA, LLC | $301.57 | 2022-2025 | Mounjaro, Zepbound |
| Amgen INC. | $201.82 | 2021-2025 | Evenity, Repatha, Repatha |
| Glaxosmithkline, LLC. | $137.30 | 2024-2025 | Trelegy Ellipta |
| Exact Sciences Corporation | $126.23 | 2024-2025 | Cologuard Collection Kit |
| Incyte Corporation | $106.28 | 2025 | Opzelura |
| Pfizer INC. | $87.48 | 2022-2025 | |
| Dynavax Technologies Corporation | $81.48 | 2024-2025 | Heplisav-B |
| Sanofi-Aventis U.S. LLC | $76.68 | 2025 | |
| Phathom Pharmaceuticals, INC. | $71.68 | 2024-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $69.57 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $53.70 | 2021-2023 | Eliquis |
| Genzyme Corporation | $39.56 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $32.61 | 2022 | |
| Si-Bone, INC. | $23.15 | 2024 | |
| Inspire Medical Systems, INC. | $20.56 | 2025 | Inspire |
| Merck Sharp & Dohme LLC | $16.93 | 2025 | Capvaxive, Gardasil 9 |
| Idorsia Pharmaceuticals US INC | $16.48 | 2024 | Quviviq |
| Horizon Therapeutics Plc | $14.66 | 2022 | |
| Alnylam Pharmaceuticals INC. | $14.51 | 2023 | Onpattro |
| Gilead Sciences, INC. | $14.14 | 2023 | |
| Organon LLC | $12.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margaux Zanetti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.